{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,2]],"date-time":"2025-12-02T11:25:41Z","timestamp":1764674741325,"version":"3.46.0"},"reference-count":23,"publisher":"Oxford University Press (OUP)","issue":"12","license":[{"start":{"date-parts":[[2025,10,24]],"date-time":"2025-10-24T00:00:00Z","timestamp":1761264000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"funder":[{"name":"Australian National Health"},{"DOI":"10.13039\/501100000265","name":"Medical Research Council","doi-asserted-by":"publisher","award":["1048312","2018071"],"award-info":[{"award-number":["1048312","2018071"]}],"id":[{"id":"10.13039\/501100000265","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000926","name":"Leukaemia Foundation Australia","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000926","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,12,2]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>To report the rates of proven, probable and possible invasive fungal disease (IFD) in patients receiving antifungal prophylaxis during initial induction and consolidation treatment of acute myeloid leukaemia (AML) plus either sorafenib or placebo.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>As part of a randomized, double-blind trial of sorafenib or placebo in combination with intensive chemotherapy for newly diagnosed adult patients with FMS-like tyrosine kinase 3-internal tandem duplication (FLT3-ITD)\u2013positive AML (ALLG AMLM16 trial), liposomal amphotericin B (LAMB) prophylaxis was administered at 5\u2005mg\/kg twice weekly during induction and consolidation phases in both sorafenib and placebo treatment arms. Alternative prophylaxis was allowed per institutional practice once sorafenib\/placebo treatment was completed. IFD episodes, reported as either a serious adverse event or an adverse event, were adjudicated.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Of the 94 patients included for analysis of IFD, four IFD episodes (one proven and three possible) were reported during the induction treatment phase. The overall rate of proven\/probable\/possible IFD was 4.3% (4\/94), with rates of 3.1% (2\/64) and 6.7% (2\/30) in the sorafenib and placebo groups, respectively. Seven patients had infusion-related reactions, and four were reported to be associated with LAMB administration.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>LAMB with or without subsequent azole prophylaxis could be an alternative option for fungal prophylaxis for patients with AML in whom azoles are contraindicated or not tolerated. Sorafenib does not appear to be associated with an increased risk of IFD.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/jac\/dkaf385","type":"journal-article","created":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T12:09:09Z","timestamp":1759320549000},"page":"3401-3406","source":"Crossref","is-referenced-by-count":0,"title":["Antifungal prophylaxis in patients with FMS-like tyrosine kinase 3-internal tandem duplication (FLT3-ITD)\u2013positive acute myeloid leukaemia receiving sorafenib during initial induction and consolidation treatment in ALLG AMLM16 trial"],"prefix":"10.1093","volume":"80","author":[{"given":"Chin Fen","family":"Neoh","sequence":"first","affiliation":[{"name":"National Centre for Infections in Cancer, Peter MacCallum Cancer Centre , Melbourne ,","place":["Australia"]},{"name":"Department of Infectious Diseases, Peter MacCallum Cancer Centre , Melbourne ,","place":["Australia"]},{"name":"Sir Peter MacCallum Department of Oncology, The University of Melbourne , Melbourne ,","place":["Australia"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michelle K","family":"Yong","sequence":"additional","affiliation":[{"name":"National Centre for Infections in Cancer, Peter MacCallum Cancer Centre , Melbourne ,","place":["Australia"]},{"name":"Department of Infectious Diseases, Peter MacCallum Cancer Centre , Melbourne ,","place":["Australia"]},{"name":"Sir Peter MacCallum Department of Oncology, The University of Melbourne , Melbourne ,","place":["Australia"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Leesa","family":"Rowley","sequence":"additional","affiliation":[{"name":"Australasian Leukaemia and Lymphoma Group (ALLG) , Melbourne ,","place":["Australia"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrew W","family":"Roberts","sequence":"additional","affiliation":[{"name":"Department of Haematology, Peter MacCallum Cancer Centre and Royal Melbourne Hospital , Melbourne ,","place":["Australia"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7171-0435","authenticated-orcid":false,"given":"Glen A","family":"Kennedy","sequence":"additional","affiliation":[{"name":"Department of Haematology, Royal Brisbane and Women\u2019s Hospital , Brisbane ,","place":["Australia"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Simon","family":"He","sequence":"additional","affiliation":[{"name":"Department of Clinical Haematology, Austin Health , Melbourne ,","place":["Australia"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anthony P","family":"Schwarer","sequence":"additional","affiliation":[{"name":"Monash University Eastern Health Clinical School , Melbourne ,","place":["Australia"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ian A","family":"Bilmon","sequence":"additional","affiliation":[{"name":"Department of Haematology, Westmead Hospital , Sydney ,","place":["Australia"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrew H","family":"Wei","sequence":"additional","affiliation":[{"name":"Department of Haematology, Peter MacCallum Cancer Centre and Royal Melbourne Hospital , Melbourne ,","place":["Australia"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8443-314X","authenticated-orcid":false,"given":"Monica A","family":"Slavin","sequence":"additional","affiliation":[{"name":"National Centre for Infections in Cancer, Peter MacCallum Cancer Centre , Melbourne ,","place":["Australia"]},{"name":"Department of Infectious Diseases, Peter MacCallum Cancer Centre , Melbourne ,","place":["Australia"]},{"name":"Sir Peter MacCallum Department of Oncology, The University of Melbourne , Melbourne ,","place":["Australia"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2025,10,24]]},"reference":[{"key":"2025120206224760800_dkaf385-B1","doi-asserted-by":"publisher","first-page":"e59","DOI":"10.1016\/S1473-3099(23)00377-8","article-title":"Consensus position statement on advancing the standardised reporting of infection events in immunocompromised patients","volume":"24","author":"Teh","year":"2024","journal-title":"Lancet Infect Dis"},{"key":"2025120206224760800_dkaf385-B2","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1111\/myc.13033","article-title":"A population-based analysis of attributable hospitalisation costs of invasive fungal diseases in haematological malignancy patients using data linkage of state-wide registry and costing databases: 2009-2015","volume":"63","author":"Valentine","year":"2020","journal-title":"Mycoses"},{"issue":"Suppl 7","key":"2025120206224760800_dkaf385-B3","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1111\/imj.15588","article-title":"Consensus guidelines for antifungal prophylaxis in haematological malignancy and haemopoietic stem cell transplantation, 2021","volume":"51","author":"Teh","year":"2021","journal-title":"Intern Med J"},{"key":"2025120206224760800_dkaf385-B4","doi-asserted-by":"publisher","first-page":"1813","DOI":"10.1093\/jac\/dkad143","article-title":"Primary prophylaxis of invasive fungal diseases in patients with haematological malignancies: 2022 update of the recommendations of the infectious diseases working party (AGIHO) of the German Society for Haematology and Medical Oncology (DGHO)","volume":"78","author":"Stemler","year":"2023","journal-title":"J Antimicrob Chemother"},{"key":"2025120206224760800_dkaf385-B5","doi-asserted-by":"publisher","first-page":"1041","DOI":"10.3201\/eid2106.140717","article-title":"Prospective multicenter international surveillance of azole resistance in Aspergillus fumigatus","volume":"21","author":"van der Linden","year":"2015","journal-title":"Emerg Infect Dis"},{"key":"2025120206224760800_dkaf385-B6","doi-asserted-by":"publisher","first-page":"1429","DOI":"10.1007\/s00277-020-04107-1","article-title":"Antifungal prophylaxis and novel drugs in acute myeloid leukemia: the midostaurin and posaconazole dilemma","volume":"99","author":"Stemler","year":"2020","journal-title":"Ann Hematol"},{"key":"2025120206224760800_dkaf385-B7","doi-asserted-by":"publisher","first-page":"2907","DOI":"10.1182\/blood-2023-189762","article-title":"Revumenib monotherapy in patients with relapsed\/refractory KMT2Ar acute leukemias: efficacy and safety results from the augment-101 phase 1\/2 study","volume":"142","author":"Aldoss","year":"2023","journal-title":"Blood"},{"key":"2025120206224760800_dkaf385-B8","doi-asserted-by":"publisher","first-page":"ofab113","DOI":"10.1093\/ofid\/ofab113","article-title":"When azoles cannot be used: the clinical effectiveness of intermittent liposomal amphotericin prophylaxis in hematology patients","volume":"8","author":"Batchelor","year":"2021","journal-title":"Open Forum Infect Dis"},{"key":"2025120206224760800_dkaf385-B9","doi-asserted-by":"publisher","first-page":"2359","DOI":"10.1093\/jac\/dkx133","article-title":"Randomized comparison of liposomal amphotericin B versus placebo to prevent invasive mycoses in acute lymphoblastic leukaemia","volume":"72","author":"Cornely","year":"2017","journal-title":"J Antimicrob Chemother"},{"key":"2025120206224760800_dkaf385-B10","doi-asserted-by":"publisher","first-page":"5089","DOI":"10.1182\/blood-2010-04-261867","article-title":"FLT3 as a therapeutic target in AML: still challenging after all these years","volume":"116","author":"Kindler","year":"2010","journal-title":"Blood"},{"key":"2025120206224760800_dkaf385-B11","doi-asserted-by":"publisher","first-page":"1856","DOI":"10.1200\/JCO.2009.25.4888","article-title":"Phase I\/II study of combination therapy with sorafenib, idarubicin, and cytarabine in younger patients with acute myeloid leukemia","volume":"28","author":"Ravandi","year":"2010","journal-title":"J Clin Oncol"},{"key":"2025120206224760800_dkaf385-B12","doi-asserted-by":"publisher","first-page":"1960","DOI":"10.1182\/blood.2023020301","article-title":"Sorafenib plus intensive chemotherapy in newly diagnosed FLT3-ITD AML: a randomized, placebo-controlled study by the ALLG","volume":"142","author":"Loo","year":"2023","journal-title":"Blood"},{"key":"2025120206224760800_dkaf385-B13","doi-asserted-by":"publisher","first-page":"1367","DOI":"10.1093\/cid\/ciz1008","article-title":"Revision and update of the consensus definitions of invasive fungal disease from the European Organization for Research and Treatment of Cancer and the Mycoses Study Group Education and Research Consortium","volume":"71","author":"Donnelly","year":"2020","journal-title":"Clin Infect Dis"},{"key":"2025120206224760800_dkaf385-B14","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1093\/jac\/dkv343","article-title":"Primary antifungal prophylaxis in adult patients with acute lymphoblastic leukaemia: a multicentre audit","volume":"71","author":"Doan","year":"2016","journal-title":"J Antimicrob Chemother"},{"key":"2025120206224760800_dkaf385-B15","doi-asserted-by":"publisher","first-page":"385","DOI":"10.3390\/jof6040385","article-title":"Safety and efficacy of intermittent high-dose liposomal amphotericin B antifungal prophylaxis in haemato-oncology: an eight-year single-centre experience and review of the literature","volume":"6","author":"Youngs","year":"2020","journal-title":"J Fungi"},{"key":"2025120206224760800_dkaf385-B16","doi-asserted-by":"publisher","first-page":"ofad424","DOI":"10.1093\/ofid\/ofad424","article-title":"Real-world use of mold-active triazole prophylaxis in the prevention of invasive fungal diseases: results from a subgroup analysis of a multicenter national registry","volume":"10","author":"Nguyen","year":"2023","journal-title":"Open Forum Infect Dis"},{"key":"2025120206224760800_dkaf385-B17","doi-asserted-by":"publisher","first-page":"348","DOI":"10.1056\/NEJMoa061094","article-title":"Posaconazole vs. fluconazole or itraconazole prophylaxis in patients with neutropenia","volume":"356","author":"Cornely","year":"2007","journal-title":"N Engl J Med"},{"key":"2025120206224760800_dkaf385-B18","doi-asserted-by":"publisher","first-page":"4043","DOI":"10.1182\/bloodadvances.2019000930","article-title":"Invasive fungal infections in acute myeloid leukemia treated with venetoclax and hypomethylating agents","volume":"3","author":"Aldoss","year":"2019","journal-title":"Blood Adv"},{"key":"2025120206224760800_dkaf385-B19","doi-asserted-by":"publisher","first-page":"583","DOI":"10.3390\/jof8060583","article-title":"High incidence of invasive fungal diseases in patients with FLT3-mutated AML treated with midostaurin: results of a multicenter observational SEIFEM study","volume":"8","author":"Cattaneo","year":"2022","journal-title":"J Fungi (Basel)"},{"key":"2025120206224760800_dkaf385-B20","doi-asserted-by":"publisher","first-page":"e361","DOI":"10.1016\/S2352-3026(22)00073-4","article-title":"Antifungal prophylaxis in adult patients with acute myeloid leukaemia treated with novel targeted therapies: a systematic review and expert consensus recommendation from the European Hematology Association","volume":"9","author":"Stemler","year":"2022","journal-title":"Lancet Haematol"},{"key":"2025120206224760800_dkaf385-B21","doi-asserted-by":"publisher","first-page":"685","DOI":"10.1007\/s00280-005-0068-6","article-title":"Lack of effect of ketoconazole-mediated CYP3A inhibition on sorafenib clinical pharmacokinetics","volume":"57","author":"Lathia","year":"2006","journal-title":"Cancer Chemother Pharmacol"},{"key":"2025120206224760800_dkaf385-B22","doi-asserted-by":"publisher","first-page":"113393","DOI":"10.1016\/j.biopha.2022.113393","article-title":"Feasibility of therapeutic drug monitoring of sorafenib in patients with liver or thyroid cancer","volume":"153","author":"Guchelaar","year":"2022","journal-title":"Biomed Pharmacother"},{"key":"2025120206224760800_dkaf385-B23","doi-asserted-by":"publisher","first-page":"2035","DOI":"10.1177\/1078155218818719","article-title":"Dose-related periorbital edema following sorafenib in a patient with acute myeloid leukemia","volume":"25","author":"Freyer","year":"2019","journal-title":"J Oncol Pharm Pract"}],"container-title":["Journal of Antimicrobial Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jac\/article-pdf\/80\/12\/3401\/64921973\/dkaf385.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jac\/article-pdf\/80\/12\/3401\/64921973\/dkaf385.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,2]],"date-time":"2025-12-02T11:22:54Z","timestamp":1764674574000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jac\/article\/80\/12\/3401\/8300672"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,24]]},"references-count":23,"journal-issue":{"issue":"12","published-online":{"date-parts":[[2025,10,24]]},"published-print":{"date-parts":[[2025,12,2]]}},"URL":"https:\/\/doi.org\/10.1093\/jac\/dkaf385","relation":{},"ISSN":["0305-7453","1460-2091"],"issn-type":[{"type":"print","value":"0305-7453"},{"type":"electronic","value":"1460-2091"}],"subject":[],"published-other":{"date-parts":[[2025,12]]},"published":{"date-parts":[[2025,10,24]]}}}